Medium impact
Policy Criteria Change
Arkansas Blue Cross Blue Shield·Effective Nov 15, 2026
Arkansas Blue Cross has added non-coverage statements for six procedures/devices across four policies effective 11/15/2026: permanently implanted prostatic stent devices (ProVee, Zenflow) for BPH; cartilage implants (Cartiva, Agili-C) and implantable shock absorbers for knee osteoarthritis; percutaneous electrical nerve field stimulation for gut-brain disorders; maternal serum cell-free RNA tests for preeclampsia/preterm birth prediction; and restricted coverage for Kerecis Omega3 (Q4158) wound dressing. All are classified as not meeting evidence criteria or investigational and will be denied for most member contracts.